Clal Insurance’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Clal Insurance’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-292,000	Closed	-$2.97M	–	159
2020 Q3	$2.97M	Hold	292,000	–	–	0.05%	93
2020 Q2	$4.35M	Hold	292,000	–	–	0.09%	89
2020 Q1	$3.56M	Buy	292,000 +287,378	+6,218%	+$4.57M	0.09%	81
2019 Q4	$292K	Sell	4,622 -287,378	-98%	-$3.67M	0.31%	62
2019 Q3	$3.59M	Sell	292,000 -16,000	-5%	-$181K	0.09%	77
2019 Q2	$4.07M	Buy	+308,000	New	+$4.49M	0.09%	70

Other funds holding PRVL

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Clal Insurance's PRVL Position: Q4 2020 in Review

Clal Insurance sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q4 2020, closing a stake of 292,000 shares — an estimated $2.97M sold.

Clal Insurance first reported a position in PRVL in Q2 2019 and held it in 6 quarters. The position peaked at $4.35M in Q2 2020. 93 funds tracked by Wall St. Rank hold PRVL as of Q4 2020.

Clal Insurance reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Clal Insurance sold 292,000 Prevail Therapeutics Inc. Common Stock shares in Q4 2020, an estimated $2.97M.
Clal Insurance first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2019 and held it in 6 quarters.
Clal Insurance's Prevail Therapeutics Inc. Common Stock position peaked at $4.35M in Q2 2020.
93 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q4 2020.

Based on Clal Insurance's 13F filing for Q4 2020, filed 16 Feb 2021.